In this online, self-learning activity:
Hospital-acquired pneumonia (HAP) occurs at an estimated rate of five to ten per 1,000 hospital admissions and is the most common cause of hospital-acquired infection in the United States. It is defined as pneumonia that develops at least 48 hours after hospital admission and did not appear to be incubating at the time of admission. A significant subset of HAP that occurs most frequently in intensive care units (ICUs) is ventilator-associated pneumonia (VAP), which is defined as pneumonia that occurs more than 48 to 72 hours after tracheal intubation and is thought to affect approximately 10 to 20% of patients who receive mechanical ventilation for more than 48 hours. Altered mechanical defenses, such as impaired ciliary motion and mucus secretion, increase the susceptibility for acquiring pneumonia in intubated patients, with over 90% of pneumonia episodes that develop in ICUs occurring in patients who are intubated or mechanically ventilated.
HCPs including: pulmonologists, infectious disease specialists, and intensivists; physician assistants, nurse practitioners, and pharmacists specializing in infectious disease or critical care; and any other healthcare professionals with an interest in or clinically encounter patients with HAP or VAP.
Commercial Support Disclosure: This program is supported by an educational grant from Shionogi Inc.
This activity is free of charge.
Release Date: August 01, 2023 -- Expiration Date: August 01, 2025
Faculty: Kusha Davar, MD, MBA, MS
Faculty introduction and disclosures
HAP/VAP refresher and primer
● Clinical presentation and diagnostic evaluation
● Epidemiology, pathogenesis, and microbiology [Learning Objective #1]
● Challenges surrounding antimicrobial resistance and understanding local resistance patterns
Treatment of HAP and VAP
● Duration of antibiotic therapy
● Optimizing initial empiric antibiotic therapy selection based on guideline recommendations, application of institutional antibiograms, and evaluation of risk factors for multidrug resistance
● Differences in coverage of antibiotic regimens and considerations related to specific agents
○ Anti-pseudomonal monotherapy vs. combination therapy
○ Novel antibiotics with broad gram-negative MDR coverage
○ Anti-MRSA agents
● Antimicrobial stewardship
○ De-escalating antibiotics based on susceptibilities
● Monitoring for clinical improvement, potential toxicities associated with certain antibiotics, and/or drug allergies
● Putting it all together: patient case(s)
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #202525264
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-23-022-H01-P. This is an Application (A)-type activity.
Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.
Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Kusha Davar, MD, MBA, MS, Assistant Program Director, Division of Infectious Diseases, Keck School of Medicine, LAC+USC Medical Center, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will NOT discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.